Dental Tribune Europe
According to Nobel Biocare Systems President Hans Geiselhöringer, scientific evidence is a priority in Nobel Biocare's product development. (Photograph: DTI)

CIDRR journal publishes scientific evidence on Nobel Biocare’s latest surface innovations

By Nobel Biocare
June 28, 2019

MADRID, Spain: With the launch of its Xeal abutment surface and TiUltra implant surface this year, Nobel Biocare recently initiated the Mucointegration era for implant dentistry. Now, clinical evidence supporting these pioneering surface innovations for soft-tissue integration has been published in a special supplement of Clinical Implant Dentistry and Related Research (CIDRR).

Scientific research building on the scientific track record of the TiUnite surface has been a key driving force behind the development of Xeal and TiUltra. The CIDRR supplement contains seven articles on the surfaces, including in vitro, preclinical and clinical studies conducted by researchers around the globe over the last five years. They focus on how clinical and biological needs must be balanced, and how surface chemistry can enhance tissue integration, as well as the Mucointegration concept. One of the studies, a randomised controlled clinical study from the Brånemark Clinic in Gothenburg in Sweden with two years of follow-up, produced promising results. It showed better soft-tissue parameters, such as statistically significantly greater mucosal height, when using the new abutment surfaces compared with machined titanium abutments.

With their unique surface chemistry and topography, Xeal and TiUltra were introduced with the goal of optimising early tissue integration and long-term tissue stability. Both surfaces are currently available in European Economic Area markets and will be released to dental professionals in other regions throughout 2019 after clearance, licensing or registration. Extending their benefits to the next generation of implants and abutments, they will also be an integral part of the company’s new Nobel Biocare N1 implant system.

According to Nobel Biocare President Hans Geiselhöringer, the Mucointegration concept is the next milestone for achieving both immediacy and longevity for successful treatment outcomes in implantology. “Having launched this next generation of dental implant and abutment surfaces with such a wealth of scientific information already available at market release, we are once again confirming our role as a company that puts science first for the benefit of patients.”

All seven studies from the CIDRR supplement are available for download from nobelbiocare.com/surface. There, dental professionals can also find more information about the clinical benefits and availability of Xeal and TiUltra.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2019 - All rights reserved - Dental Tribune International